TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07450859: A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Sponsor: BicycleTx Limited · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 39 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,755,600

Rescue Site Savings

+$1,155,000

Unlock Full NCT07450859 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07450859 Rescue Dossier →